1. Friction-cost method as an alternative to the human-capital approach in calculating indirect costs

   • Howard Birnbaum

   Editorial 17 September 2012 Pages: 103 - 104

2. The friction-cost method

   • Werner B. F. Brouwer
   • Marc A. Koopmanschap

   Current Opinion 17 September 2012 Pages: 105 - 111

3. The diffusion of health economics knowledge in Europe

   • Gérard de Pouvourville
   • Philippe Ulmann
   • Michael Drummond

   Leading Article 17 September 2012 Pages: 113 - 120

   

4. The case for stratified cost-effectiveness analysis by baseline health-related QOL

   • Joseph Schaafsma

   Leading Article 17 September 2012 Pages: 121 - 132

   

5. Cost effectiveness of treating low HDL-cholesterol in the primary prevention of coronary heart disease

   • Joel W. Hay
   • Kimberly L. Sterling

   Original Research Article 17 September 2012 Pages: 133 - 141

   

6. Providing systematic guidance in pharmacoeconomic guidelines for analysing costs

   • Philip Jacobs
   • Arto Ohinmaa
   • Bruce Brady

   Original Research Article 17 September 2012 Pages: 143 - 153

   

7. Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder

   • José-Luis Fernandez
   • Stuart Montgomery
   • Clément Francois

   Original Research Article 17 September 2012 Pages: 155 - 167

   

8. Cost-minimisation analysis of sivelestat for acute lung injury associated with systemic inflammatory response syndrome

   • Naoki Aikawa
   • Seitaro Fujishima
   • Taira Abiru

   Original Research Article 17 September 2012 Pages: 169 - 181

   

9. The impact of anaemia and its treatment on employee disability and medical costs

   • Ernst Berndt
   • William Crown
   • Gary H. Lyman

   Original Research Article 17 September 2012 Pages: 183 - 192

   

10. Memantine

    • Greg L. Plosker
    • Katherine A. Lyseng-Williamson

    Adis Pharmacoeconomic Drug Evaluation 17 September 2012 Pages: 193 - 206